Literature DB >> 31183211

Concomitant KRAS and BRAF mutations in colorectal cancer.

Lauren Midthun1, Shagufta Shaheen2, Jeremy Deisch3, Maheswari Senthil4, James Tsai5, Chung-Tsen Hsueh5.   

Abstract

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAP-kinase signaling pathway. While previously considered mutually exclusive, concomitant mutations in both KRAS and BRAF genes have been identified in colorectal cancer (CRC). The clinical outcome of these patients remains undetermined. We present the clinical course of two patients with CRC harboring mutations at codon 12 of KRAS and BRAF non-V600E mutations. More research is needed to determine the clinical-pathological effect of these simultaneous mutations of KRAS and BRAF in CRC on disease course and treatment outcome.

Entities:  

Keywords:  BRAF; KRAS; colorectal cancer (CRC)

Year:  2019        PMID： 31183211      PMCID： PMC6534722          DOI： 10.21037/jgo.2019.01.10

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  17 in total

1.  KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.

Authors:  C Oliveira; S Velho; C Moutinho; A Ferreira; A Preto; E Domingo; A F Capelinha; A Duval; R Hamelin; J C Machado; S Schwartz; F Carneiro; R Seruca
Journal:  Oncogene       Date:  2006-09-04       Impact factor: 9.867

2.  KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.

Authors:  D P Modest; P Camaj; V Heinemann; B Schwarz; A Jung; R P Laubender; S Gamba; C Haertl; S Stintzing; S Primo; C J Bruns
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

Review 3.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Authors:  M J Sorich; M D Wiese; A Rowland; G Kichenadasse; R A McKinnon; C S Karapetis
Journal:  Ann Oncol       Date:  2014-08-12       Impact factor: 32.976

4.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

5.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

6.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

7.  A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Authors:  Akihito Kawazoe; Kohei Shitara; Shota Fukuoka; Yasutoshi Kuboki; Hideaki Bando; Wataru Okamoto; Takashi Kojima; Nozomu Fuse; Takeharu Yamanaka; Toshihiko Doi; Atsushi Ohtsu; Takayuki Yoshino
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

Review 8.  BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.

Authors:  Eftychia Oikonomou; Evangelos Koustas; Maria Goulielmaki; Alexander Pintzas
Journal:  Oncotarget       Date:  2014-12-15

9.  Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature.

Authors:  Ibrahim Halil Sahin; Syed M A Kazmi; Jeffrey T Yorio; Nishin A Bhadkamkar; Bryan K Kee; Christopher R Garrett
Journal:  J Cancer       Date:  2013-03-28       Impact factor: 4.207

10.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Authors:  Roland Houben; Jürgen C Becker; Andreas Kappel; Patrick Terheyden; Eva-B Bröcker; Rudolf Goetz; Ulf R Rapp
Journal:  J Carcinog       Date:  2004-03-26
View more
  12 in total

1.  Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?

Authors:  Cristiane J Gomes-Lima; Leila Shobab; Di Wu; Dorina Ylli; Athanasios Bikas; Matthew McCoy; Rebecca Feldman; Wen Lee; Sarika N Rao; Kirk Jensen; Vasily Vasko; Luiz Claudio Castro; Jacqueline Jonklaas; Leonard Wartofsky; Kenneth D Burman
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

2.  A Cross-Sectional Study for Evaluation of KRAS and BRAF Mutations by Reverse Dot Blot, PCR-RFLP, and Allele-Specific PCR Methods Among Patients with Colorectal Cancer.

Authors:  Fatemeh Sheikhsofla; Behzad Poopak; Sajjad Firuzyar; Fatemeh Roudbari; Mojtaba Ghadiany
Journal:  Avicenna J Med Biotechnol       Date:  2021 Oct-Dec

3.  Relevance of gene mutations and methylation to the growth of pancreatic intraductal papillary mucinous neoplasms based on pyrosequencing.

Authors:  Go Asano; Katsuyuki Miyabe; Hiroyuki Kato; Michihiro Yoshida; Takeshi Sawada; Yasuyuki Okamoto; Hidenori Sahashi; Naoki Atsuta; Kenta Kachi; Akihisa Kato; Naruomi Jinno; Makoto Natsume; Yasuki Hori; Itaru Naitoh; Kazuki Hayashi; Yoichi Matsuo; Satoru Takahashi; Hiromu Suzuki; Hiromi Kataoka
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

4.  Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study.

Authors:  Shiro Uchida; Takaaki Kojima; Takashi Sugino
Journal:  Pathol Oncol Res       Date:  2022-02-24       Impact factor: 3.201

Review 5.  Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.

Authors:  Octav Ginghina; Ariana Hudita; Marius Zamfir; Andrada Spanu; Mara Mardare; Irina Bondoc; Laura Buburuzan; Sergiu Emil Georgescu; Marieta Costache; Carolina Negrei; Cornelia Nitipir; Bianca Galateanu
Journal:  Front Oncol       Date:  2022-03-08       Impact factor: 6.244

6.  Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report.

Authors:  Veronica Zelli; Alessandro Parisi; Leonardo Patruno; Katia Cannita; Corrado Ficorella; Carla Luzi; Chiara Compagnoni; Francesca Zazzeroni; Edoardo Alesse; Alessandra Tessitore
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

7.  KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.

Authors:  Nuria Garcia-Carbonero; Javier Martinez-Useros; Weiyao Li; Alberto Orta; Nuria Perez; Cristina Carames; Tatiana Hernandez; Irene Moreno; Gloria Serrano; Jesus Garcia-Foncillas
Journal:  Cells       Date:  2020-01-15       Impact factor: 6.600

8.  Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.

Authors:  Nana Lyu; Vinoth Kumar Rajendran; Russell J Diefenbach; Kellie Charles; Stephen J Clarke; Alexander Engel; Helen Rizos; Mark P Molloy; Yuling Wang
Journal:  Nanotheranostics       Date:  2020-08-25

9.  Epidemiology characteristics of ethnic minority colorectal cancer in Yunnan in Southwestern China.

Authors:  Shaoxiang Wan; Qi Tang; Daying Feng; Zaoxiu Hu; Weiqing Shao; Yajuan Chen
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 0.496

10.  Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.

Authors:  XuSha Zhou; Jing Zhao; Jian V Zhang; Yinglin Wu; Lei Wang; Xiaoqing Chen; Dongmei Ji; Grace Guoying Zhou
Journal:  Viruses       Date:  2021-09-03       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.